Groundbreaking funding promises to revolutionize care for patients with advanced prostate cancer by addressing treatment resistance through innovative liquid biopsy technology.
Novigenix, a leader in AI-driven healthcare solutions, has today announced the approval of a Eurostars grant for the MYeloid SIGNATUREs (MY-SIGNATURE) project. This prestigious grant, totaling a consortium budget of €1.75 million, will support the development of MYELO-SCAN, the world’s first liquid biopsy test designed to predict intratumoral myeloid-derived suppressor cell (MDSC) infiltration in metastatic castration-resistant prostate cancer (mCRPC) patients.
Novigenix will lead the MY-SIGNATURE consortiumin collaboration with the Dutch subsidiary of Crown Bioscience and the “Precision Medicine in Genito-Urinary Cancers” research group led by Dr. Niven Mehra, Associate Professor in Medical Oncology at Radboud University and a key opinion leader in immuno-oncology. The project will start on October 1, 2024. The MYELO-SCAN test aims to revolutionize precision therapy by developing a validated prototype for predicting MDSC infiltration, a critical factor in treatment resistance for mCRPC patients.
